Introduction
Exposure of human cancer cells to dierentiationinducing compounds may lead to morphological maturation, a decrease in the rate of proliferation, inhibition of clonogenicity, programmed cell death (apoptosis) and a reduced ability to form tumors in immunode®cient athymic mice. The biochemical and molecular mechanisms that govern dierentiation have been studied in a large number of cell models including the HL-60 human promyelocytic leukemia cell line that can be induced to dierentiate towards their nondividing cellular counterparts by a variety of structurally unrelated compounds. The HL-60 cell line is primarily composed of promyelocytes (Collins et al., 1978) , which can be induced to dierentiate along the myeloid pathway into granulocytes after treatment with all-trans retinoic acid (RA) (Collins et al., 1978; Breitman et al., 1980) , towards neutrophils after treatment with dimethylformamide (DMF) (Dexter et al., 1979) and to monocytes/macrophages after exposure to phorbol esters (Rovera et al., 1979) .
In general, upon dierentiation, tumor cells exhibit a decreased ability or inability to form tumors in vivo. For example, human leukemia U937 and malignant melanoma SB1B cells, xenografted in immunode®cient mice generated tumors, whereas dierentiated counterparts of these cells had lost their tumorigenic ability (Pantazis et al., 1994 . The results obtained from studies with leukemic cell lines indicate that there exist multiple pathways of inducing dierentiation in susceptible cells in vitro but unfortunately, dierentiation-therapy has met with limited success in the clinic (Olsson et al., 1996) . Thus, while all-trans retinoic acid (ATRA) therapy induced complete remission in approximately 75 to 85% of patients with acute promyelocytic leukemia (Huang et al., 1988; Castaigne et al., 1990; Warrell et al., 1991) , approximately 25% of these patients developed an often fatal retionic acid syndrome (Warrell et al., 1991; Frankel et al., 1992) , that appeared to correlate with increased numbers of dierentiating cells, i.e., leukocytes, and their diuse in®ltration into tissues (Frankel et al., 1992) . Therefore, the unfavorable therapeutic outcome of dierentiation-based therapy was due to the supernumerary dierentiated cells rather than the failure to induce dierentiation.
Apoptosis, in addition to dierentiation, is another important regulatory mechanism for determining a cancer cell's fate. Intriguingly, the apoptotic and dierentiation pathways often seem to intersect. Thus, leukemic HL-60 cells undergo apoptosis after exposure to a variety of agents that induce dierentiation (Martin et al., 1990) . While the exact molecular mechanisms associated with dierentiation-induction in myeloid cells and the regulation of the apoptotic program have not been fully elucidated, they apparently overlap. In particular, the Bcl-2 family of oncoproteins appears to play critical roles in both of these processes.
In the case of apoptosis, Bcl-2 family members can suppress or enhance apoptosis in many mammalian cells, including those of hematopoietic origin (Hockenberry et al., 1990) , and therefore can serve either as death antagonists (Bcl-2, Bcl-x L , Bcl-w, B¯-1, Brag-1, Mcl-1 and A1) or death agonists (Bax, Bak, Bad, Bid, Bik, Hrk and Bcl-x S ) (Yang and Korsmeyer, 1996; Kroemer, 1997) , respectively. A characteristic feature of the Bcl-2 family proteins is the formation of homoand hetero-dimers which alter the apoptotic regulatory status of a cell and determines the resistance or susceptibility of a cell to undergo cell death. For example, Bad (Yang et al., 1995) and Bax (Boise et al., 1993; Oltvai et al., 1993) can inhibit the anti-apoptotic function of Bcl-2 and Bcl-x L , and similarly, the apoptotic eector Bak can promote cell death via binding with Bcl-2 or Bcl-x L (Chittenden et al., 1995a,b; Farrow et al., 1995; Kiefer et al., 1995; Sattler et al., 1997) . Recent evidence has demonstrated that many Bcl-2 family members are localized to multiple membrane compartments including the outer membranes of mitochondria (Krajewski et al., 1993; Gonzalez-Garcia et al., 1994) where they can form ion channels (Hockenberry et al., 1990; Minn et al., 1997; Schendel et al., 1997) . In the mitochondria, the induction of apoptotic cell death is promoted by the release of cytochrome c from the intermembrane space into the cytosol (Liu et al., 1996) , and its subsequent association with the Apaf-1/caspase-9 complex resulting in the activation of procaspase-3 (Li et al., 1997; Zou et al., 1997) . The activation of caspase-3 leads to the cleavage of other death substrates, cellular and morphological changes and ultimately cell death (Li et al., 1997) . In mitochondria, overexpression of Bcl-2 and Bcl-x L can suppress mitochondrial dysfunction such as membrane potential loss, the release of cytochrome c and the activation of caspase-3 (Yang et al., 1997; Kluck et al., 1997) . Therefore, the balance between apoptotic eector and suppressor proteins in the mitochondria appears to impact the ability of a cell to undergo apoptosis.
The Bcl-2 family of proteins have also been implicated in the process of hematopoietic dierentiation (Sentman et al., 1991; Delia et al., 1992; Campana et al., 1993) . In HL-60 cells, dierentiation-induction results in the suppression of Bcl-2 and apoptosis (Benito et al., 1995) , while ectopically expressed Bcl-2 blocks chemotherapy-induced apoptosis in human pre-B leukemia and myeloid cells (Miyashita and Reed, 1993; Naumovski and Cleary, 1994; Park et al., 1994; Delia et al., 1995) . Dierentiation of HL-60 cells with phorbol esters results in the induction of Bcl-x L and correlates with the longer survival of monocytes and macrophages (Sanz et al., 1997; Chatterjee et al., 1997) . The apoptotic eector Bak regulates cell death at speci®c stages of cell dierentiation through tissuespeci®c control of its expression (Krajewski et al., 1996) . In myeloid cells, Bak is highly expressed in terminally dierentiated granulocytes that will ultimately undergo apoptosis, but only slightly in progenitor bone marrow cells (Krajewski et al., 1996) . Thus, while the precise function of Bcl-2 family of proteins in hematopoietic dierentiation is unclear, it is apparent that the regulation of these proteins plays critical roles for determining the fate of terminally dierentiated hematopoietic cells.
In this communication, we demonstrate that monocytic dierentiation of HCW-2 cells results in the induction and stabilization of Bak and its localization to the mitochondria. These events correlate with the susceptibility of dierentiated HCW-2 cells to undergo apoptosis when induced. When bak is transiently expressed in HCW-2 cells, STS treatment also results in apoptotic induction. Therefore, the induction and mitochondrial localization of Bak appear to be required to activate apoptosis in monocytic HCW-2 leukemia cells.
Results

HCW-2 cells resist granulocytic but not monocytic differentiation
HCW-2 cells were derived from the HL-60 cell line and shown to be refractory to the apoptotic eect of numerous compounds (Han et al., 1996) . However, the ability of these cells to dierentiate had not been previously assessed and, therefore, we investigated whether HCW-2 cells would respond to treatment with compounds that induce dierentiation of HL-60 cells. Whereas the parental HL-60 cells were sensitive to the growth-inhibitory and dierentiation-induction eects of RA, DMF and PMA as measured by the NBT reduction assay, HCW-2 cells were refractory to the growth-inhibitory and dierentiation-induction eects of RA and DMF, but not PMA (Table 1) . The dierentiation of PMA-treated HCW-2 cells to monocytes was con®rmed by the presence of c-fms mRNA, which was undetected in untreated and RAtreated cells (Figure 1a) . The c-fms mRNA species is primarily present in peripheral blood monocytes, tissue macrophages and their committed bone marrow progenitors (Sherr et al., 1985) . PMA-treated HCW-2 cells also attached to the surface of the culture dish and developed a monocytic appearance when compared to untreated HCW-2 cells (Figure 1b ). These data demonstrated that HCW-2 cells were capable of dierentiating along the monocyte/macrophage lineage.
Induction of apoptosis in PMA-treated HCW-2 cells
Since HL-60 cells rapidly die by apoptosis in the presence of staurosporine (STS) whereas HCW-2 cells are resistant (Han et al., 1996) , we investigated if the dierentiation of HCW-2 cells to monocytes rendered these cells susceptible to STS-induced apoptosis. For these experiments, we monitored events that have been associated with apoptosis in HL-60 cells including eux of cytochrome c from the mitochondria into the cytoplasm, and the activation of procaspase-3 . We prepared and analysed cytosolic extracts (S-100) from untreated cells, and cells treated with 5 mM STS for 4 h; 100 nM PMA for 4 days; and PMA for 4 days followed by STS treatment for 4 h. Exposure of PMA-treated HCW-2 cells with STS for 4 h resulted in detection of cytochrome c in the cytoplasm and loss of procaspase-3, indicative of caspase-3 activation ( Figure 2a ). This process was correlated with the diminution of full-length Bid, suggesting the involvement of truncated Bid (t-Bid) in the process of cytochrome c eux (Luo et al., 1998) . Using the ApoAlert CPP-32¯uorescent assay kit, it was con®rmed that induction of caspase-3 activity was 8 ± 9-fold higher in HCW-2 cells treated with PMA+STS than in untreated, PMA-or STS-treated cells ( Figure 2b ). Finally, detection of condensed chromatin by DAPI staining and loss of mitochondrial integrity and depolarization measured by rhodamine-123 staining were noted only in the PMA+STS-treated HCW-2 cells (data not shown). We concluded that monocytic dierentiation of HCW-2 cells induced by PMA treatment rendered them susceptible to apoptosis.
Induction and mitochondrial localization of Bak in PMA-treated HCW-2 cells
The ability of PMA-dierentiated HCW-2 cells to undergo apoptosis when treated with STS correlated with the release of cytochrome c from the mitochondria and suggested that one mechanism to account for these changes may have been the alteration in the levels of Bcl-2 family members associated with the mitochondria after PMA-mediated dierentiation. HCW-2 cells do not express Bcl-2 (Han et al., 1996) . In addition, no signi®cant alterations were observed in the levels of Bad and Bax (Figure 3a) in the mitochondrial or S-100 extracts from PMA-treated HCW-2 cells when compared to untreated cells. We observed a modest reduction in the mitochondria and a slight increase in the S-100 fraction in the levels of Bcl-x L after PMA treatment (Figure 3a) . Moreover, we observed a robust increase of Bak in the mitochondria of PMA-treated HCW-2 cells (Figure 3a) . To determine if the induction and localization of Bak was monocyte-speci®c, we examined the mitochondrial status of Bak in HL-60, THP-1 and K562 leukemic cells after treatment with PMA for 4 days. Mitochondrial Bak was elevated in myeloid cells (HL-60, THP-1) that dierentiated to monocytes, whereas K562 cells, which dierentiated to megakaryocytes after PMA treatment did not display an increase of Bak (Figure 3b ). These results suggested that the up-regulation of mitochondrial Bak expression occurs speci®cally during the dierentiation of myeloid cells to monocytes.
Mechanism of Bak induction in monocytic HCW-2 cells
The ®ndings described above prompted us to investigate the mechanism of Bak-induction in HCW-2 cells. Nuclear run-on assays were performed in untreated and 4 day PMA-treated HCW-2 cells to determine if PMA induced the transcription of bak. The results showed that the rate of transcription of bak, bad and GAPDH mRNA species as not altered by PMAtreatment ( Figure 4 ). To investigate whether the stability of bak mRNA was altered in PMA-treated cells, we performed semi-quantitative hot start RT ± PCR and observed an increase in the steady-state level of bak mRNA after 4 days of PMA treatment in HCW-2 cells when compared to untreated cells (Figure 5a ). The halflife of bak mRNA was determined in untreated and 4 day PMA-treated HCW-2 cells by blocking transcription in the presence of actinomycin D and monitoring the rate of mRNA degradation by RT ± PCR. The average value of three separate experiments indicated that the half-life of bak was approximately 6 h and greater than 24 h in the untreated and PMA-treated cells, respectively ( Figure  5b ). No signi®cant changes were observed in the stability of bad, bcl-x L and bcl-x s mRNAs in PMA-treated HCW-2 cells exposed to actinomycin D (Figure 5c ). We concluded that monocytic dierentiation of HCW-2 cells correlated with extensive stabilization of bak mRNA.
Transient transfection of bak results in apoptosis in STS-treated HCW-2 cells
The experiments described above suggested that the expression of Bak represents a critical factor for the change in apoptotic sensitivity of HCW-2 cells. This For this study, an expression vector was constructed containing the full-length human bak cDNA and transiently transfected into HCW-2 cells. As a control, HCW-2 cells were also transfected with an empty expression vector. Two days post-transfection, the medium was removed from bak-and empty vectortransfected HCW-2 cells and both cell cultures were treated with STS for 4 h. Cell extracts were prepared and analysed for the expression of procaspase-3, cytochrome c and Bak via Western blot analysis. In bak, but not control vector, transfected cells there was a signi®cant increase in the amount of Bak, processing of procaspase-3 and eux of cytochrome c (Figure 6a ). The expression of actin was unaltered underscoring the apoptotic speci®city of the bak transgene. DNA fragmentation was also only observed in bak-transfected cells treated with STS ( Figure 6b ). We concluded from these experiments that the transient expression of bak alters the susceptibility of HCW-2 cells to undergo STS-mediated apoptosis.
Discussion
We have examined the consequence of dierentiationinduction in an apoptotic-resistant cell variant, HCW-2, derived from the HL-60 promyelocytic cell line. Initially, we determined that RA-and DMF-treated HCW-2 cells did not dierentiate along the myeloidspeci®c lineages of granulocytes and neutrophils, respectively. Importantly, RA and DMF also did not induce apoptosis in HCW-2 cells. In contrast, exposure of HCW-2 cells to PMA-induced dierentiation along the myelomonocytic lineage concomitant with an increase in the mitochondrial localization of the Bak which alters the susceptibility of HCW-2 cells to apoptosis induction. The induction of Bak expression has previously been observed in HL-60 cells that had dierentiated after treatment with dimethylsulfoxide or the phorbol ester 12,13-phorbol dibutyric acid (Chatterjee et al., 1997 ). Here we demonstrate that in HCW-2 cells induced to dierentiate by PMA treatment the altered Bak expression is largely due to the signi®cant stabilization of bak mRNA ( Figure 5 ). The stabilization of apoptosis-associated mRNAs has also been observed in other cell systems. For example, bcl-x L is stabilized in human gastric cells treated with dexamethasone , and bcl-2, bcl-x L and bax are stabilized during liver regeneration (Kren et al., 1998) . Stabilization of apoptosis-associated genes during myeloid dierentiation has not been reported. PMA treatment, however, can stabilize TIMP-1 during the dierentiation of U937 cells (Doyle et al., 1997) and IL-2 in Jurkat cells . Thus, although the stabilization of bak mRNA following PMAinduced dierentiation may not represent an unique event per se, it clearly represents a potential mechanism for the development of an apoptotic permissive environment in HCW-2 cells.
The Bak protein in dierentiated HCW-2 cells is exclusively localized to the mitochondria (Figure 3) . One consequence of this localization may be to reduce the amount of active Bcl-x L . We have preliminary evidence to demonstrate that Bak associates with Bclx L in monocytic HCW-2 cells (data not shown). Since high concentrations of Bak (Chittenden et al., 1995a; Farrow et al., 1995; Kiefer et al., 1995) as well as the Bak BH3 domain peptide (Holinger et al., 1999) can antagonize the anti-apoptotic function of Bcl-x L , it is reasonable to hypothesize that increasing the ratio of Bak:Bcl-x L to`free' Bcl-x L after monocytic dierentiation increases the susceptibility of HCW-2 cells to apoptosis induction. However, our results do not rule out the involvement of other proteins, in addition to Bak, including Bok (Hsu et al., 1997; Inohara et al., 1998 ), Bim (O'Connor et al., 1998 , Blk (Hegde et al., 1998) , Bik/Nbk (Boyd et al., 1995) , etc. in the sensitization of PMA-derived monocytic HCW-2 cells to undergo apoptosis.
It has been reported that Bax, when overexpressed in some cell types, also localizes to the mitochondria, induces the release of cytochrome c (Rosse et al., 1998; Jurgenmeier et al., 1998) , and aects the mitochondrial permeability transition (Pastorino et al., 1998) . In addition, recombinant Bax and Bak can induce mitochondrial DC loss, swelling and cytochrome c release, which can be prevented by overexpressing recombinant Bcl-x L as well as transgene-derived Bcl-2 (Narita et al., 1998) . Furthermore, co-immunoprecipitation studies demonstrated that Bax and Bak interacted with the voltage-dependent anion channel, which is a component of the mitochondrial permeability transition (PT) pore (Narita et al., 1998) . The release of apoptogenic cytochrome c by recombinant Bak and Bax has also been attributed to the ability of these proteins to accelerate the opening of voltage-dependent anion channel (VDAC), which recombinant Bcl-x L has the ability to close, and prevent the pro-apoptotic activities of Bax and Bak . Lastly, it has been demon- (7) or treated with (+) PMA-treatment Figure 4 Lack of transcriptional activation of bak after PMA treatment. Nuclear run-on assays were performed in untreated (7) and 4 day PMA-treated (+) HCW-2 cells as described in Materials and methods. The relative amounts of in vitro radiolabeled bak, bad and GAPDH transcripts were determined by dot-blot hybridization strated that Bak can accelerate cell death independent of binding with Bcl-x L and Bcl-2 (Simonian et al., 1997) . Theoretically, therefore, in HCW-2 cells, the induction and mitochondrial localization of Bak upon PMA treatment (Figure 3 ) may regulate VDAC and PT as well as neutralize Bcl-x L to allow HCW-2 cells to become susceptible to apoptosis induction. While these nuances of PMA induction will require additional investigation, our preliminary data nonetheless suggest that PMA treatment of human promyelocytic leukemia cells alters the critical ratio between Bak and Bcl-x L (Figure 3) . Figure 5 Enhanced stabilization of bak mRNA in PMA-treated HCW-2 cells. (a) RT ± PCR analysis was performed on total RNA isolated from untreated and 4 day PMA-treated HCW-2 cells as described in Materials and methods. (b) Untreated and 4 day PMA-treated HCW-2 cells were exposed to 5 mg/ml actinomycin D for the indicated times. RT ± PCR analysis was performed with gene-speci®c primers as described in Materials and methods. The plotted data represent the mean+standard deviation of three independent experiments. The agarose gels show one such experiment. Note: The standard deviations for the PMA-treated samples are not evident because of the scale. (c) The same experiment as described in (b) was repeated for bad, bcl-x L and bcl-x S . Note: A longer exposure time of the gels was required for measuring bcl-x L,S Lack of apoptosis-induction by chemotherapeutic agents may result from de®ciencies in the pathway(s) of apoptotic signaling or execution. Although it has been reported that dierentiation induction can render cells resistant to drug-induced apoptosis (Solary et al., 1993; Sordet et al., 1999) , this study demonstrates that modulation of an apoptotic eector protein, Bak, through the use of phorbol esters, may increase the susceptibility and lead to the abrogation in resistance to apoptotic cell death. The clinical relevance of our ®ndings is supported by recent reports that intravenous administration of PMA in patients with myelocytic leukemia resulted in the remission of this disease in some patients refractory to treatments with all-trans retinoic acid, cytosine arabinoside and other chemotherapeutic agents (Han et al., 1998b) . Therefore, the results collectively suggest that (1) phorbol esters can be used, at low cytostatic doses, alone or in combination with other chemotherapeutic agents, and (2) the regulation of apoptosis eectors, such as Bak, may reverse the susceptibility of cell variants resistant to apoptosis/chemotherapy. Altering the balance between apoptosis sensitivity and resistance by exploiting this type of mechanism may improve the ecacy of currently used strategies in leukemia therapy.
Materials and methods
Materials
All tissue culture supplies (Corning brand) used in this study were obtained from VWR Scienti®c Inc. (Bridgeport, NJ, USA). Fetal bovine serum (FBS), RPMI 1640 medium, actinomycin D, dimethylformamide (DMF), trans-retinoic acid (RA), nitroblue tetrazolium (NBT), phorbol myristate acetate (PMA), phorbol 12,13-dibutyrate (PDBu) and staurosporine (STS) were purchased from the Sigma Chemical Co. (St. Louis, MO, USA).
Cells
The human leukemia cell lines, HL-60, THP-1 and K562 were cultured in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml of penicillin and 50 U/ml of streptomycin. The isolation, characterization and culture conditions of the HCW-2 cell line have been reported (Han et al., 1996) . All cell cultures were maintained in a humidi®ed incubator with 5% CO 2 , 95% air at 378C. Terminally dierentiated cells were identi®ed by the NBT-staining technique (Breitman, 1990 ).
Western blot analysis
The protocol used for Western blot analysis has been reported (Han et al., 1996) . The polyclonal antibody which detects Bcl-x L was kindly provided by Dr Craig Thompson (Penn. University of Philadelphia, PA, USA); Bcl-2 and Bak antibodies were purchased from Calbiochem (Cambridge, MA, USA); Bax antibody was purchased from PanVera Corporation (Madison, WI, USA); Bid antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); caspase-3 and Bad antibodies were purchased from Transduction Laboratories, Inc. (Lexington, KY, USA); the monoclonal antibody to cytochrome c was kindly provided by Dr R Jemmerson (University of Minnesota, MN, USA). Western blots were analysed by the Amersham chemiluminescence kit.
Northern blot analysis
Isolation of total cellular RNA, Northern blot analysis and conditions used for prehybridization, hybridization and blot washing have been described (Han et al., 1996) . The cDNA probe used to detect the expression of c-fms was provided by Dr Donald Kufe (Dana-Farber Cancer Institute, Boston, MA, USA). The GAPDH probe has been described elsewhere (Han et al., 1996) .
Nuclear run-on assay
The protocol for this assay has been described (Chatterjee et al., 1989) . Brie¯y, pelleted nuclei were resuspended in storage Extracts were prepared from the experimental conditions reported in (a) and analysed for integrity of chromosomal DNA by agarose gel electrophoresis. Lane M, 100-bp markers buer containing (50 mM Tris, pH 8.3, 40% glycerol, 5 mM MgCl 2 , 0.1 mM EDTA. 32 P-radiolabeled nuclear run-on transcripts were prepared from equal quantities of nuclei (30 mg DNA) from untreated and PMA-treated HCW-2 cells. Nuclei were suspended in 26 transcription buer (10 mM Tris, pH 8.0, 5 mM MgCl 2 , 0.3 M KCl, 0.8 mg heparin, 5 mM DTT, 1 mM of ATP, CTP and GTP, 24 mCi 32 P-UTP, 0.05 ml RNasin), mixed gently, and incubated at 378C for 30 min. Transcription was stopped by the addition of 400 ml of a solution which contained 4 M guanidium thiocyanate, 25 mM sodium citrate, pH 7.0, 0.5% sarcosyl, 0.1 M b-mercaptoethanol, 400 ml saturated phenol, and 100 ml chloroform. The sample was vortexed for 1 min and centrifuged at 11 000 g for 15 min. The aqueous layer was removed and mixed with 0.22 mg of tRNA and two volumes of isopropanol. The RNA was precipitated at 7208C for 2 h and collected by centrifugation at 11 000 g for 15 min. The pellet was washed with 70% ethanol, air dried for 15 min and dissolved in 16 TE. Unincorporated nucleotides were removed by centrifugation through a G25 column (Boehringer Mannheim, Indianapolis, IN, USA). Run-on transcripts prepared in this manner were hybridized to the appropriate target DNA.
The bak cDNA was provided by Dr Michael Kiefer (LXR, Inc, Richmond, CA, USA) and the plasmid for bad was provided by Dr Stanley Korsmeyer (Dana Farber Cancer Institute, Boston, MA, USA). Target DNAs were linearized with the appropriate restriction endonucleases, precipitated, resuspended in TE and immobilized onto nitrocellulose using a dot-blot apparatus (Gibco BRL, Gaithersburg, MD, USA). The nitrocellulose ®lter containing DNA was UV-crosslinked (Stratagene) and prehybridized at 428C for 2 h in a hybridization solution containing 50% formamide, 0.5% milk powder, 0.5 mM NaPO 4 , 56 SSC, 10% dextran sulfate, 1% SDS, 0.5 mg/mL salmon sperm DNA. The in vitro transcribed 32 P-radiolabeled RNA was added and allowed to hybridize for 48 h at 428C. The ®lters were washed for 10 min at room temperature with 26 SSC, 10 min with 26 SSC containing 0.1% SDS, 20 min with 0.16 SSC containing 1% SDS and rinsed with 26 SSC.
RT ± PCR assays
HCW-2 cells were treated with PMA for various intervals, total RNA was isolated and 5 mg used for ®rst-strand synthesis which then served as a template for PCR reactions using a 1st Strand cDNA Synthesis kit purchased from Boehringer Mannheim (Indianapolis, IN, USA). The Bak PCR primers were 5'-ACTACAGGTGAAGGCTCTCACC-3' and 5'-CAATAGAGAAGGCACTGTCACC-3'; the bactin PCR primers were 5'-ATCTGGCACCAGACCTTC-TACAATGAGCTGCG-3' and 5'-CGTCATACTCCTGCT-TGCTGATCCACATCTGC-3'; Bad primers were: 5'-CCT-TTAAGAAGGGACTTCCTCGCC-3' and 5'-ACTTCCGA-TGGGACCAAGCCTTCC-3'; and Bcl-x L,S primers (Rokhlin et al., 1997) used were: 5'-AGATCTGAATTCGTAAAG-CAAGCGCTGAGGG-3' and 5'-AGATCTAAGCTTGAA-GAGTGAGCCCCAGCAGACC-3'. The PCR products were analysed on 2% agarose gels containing ethidium bromide.
Analysis of mRNA stability
Total RNA was isolated from untreated or 4 day PMAtreated HCW-2 cells that had been exposed to 5 mg/mL of actinomycin D for 0.5, 1, 3, 6, 12 and 24 h. RT ± PCR analysis was performed as described. The levels of bak mRNA in untreated and PMA-treated HCW-2 cells were determined by densitometry and utilized to calculate the halflife for both samples.
Fractionation of cells
Cells were fractionated as described (Han et al., 1998a) and the cell lysate was divided into two equal volumes. One volume was used to isolate nuclei and mitochondria by mixing with 30 volumes of lysis buer containing 0.25 M sucrose. The mixture was centrifuged at 500 g for 10 min at 48C and the nuclei-free supernatant was centrifuged again at 10 000 g for 20 min at 48C to obtain the fraction containing mitochondria. The other half volume of the lysate was immediately centrifuged at 12 500 g for 15 min and the supernatant was carefully removed and recentrifuged at 100 000 g for 1 h at 48C. The clari®ed supernatant was used as the membrane-free cytosolic (S-100) extract and the pellet as the light membrane fraction.
Construction and transfection of bak expression vector
The 986 bp cDNA for bak was excised from plasmid cdn-1 (provided by Dr Michael Kiefer, LXR Inc., Richmond, CA, USA) and cloned into the BamHI ± HindIII site of plasmid pcDNA 3.1(7) (Invitrogen, Carlsbad, CA, USA). Plasmid cDNA was puri®ed using the Qiagen Maxi plasmid Kit (Qiagen, Valencia, CA, USA). Vector and bak expression plasmids were transiently transfected into HCW-2 cells in 6-well plates using 4 mg of pc-bak cDNA and a charge ratio of 1 : 1, using the TransFast transfection reagent (Promega, Madison, WI, USA) following the protocol recommended by the manufacturer.
DNA fragmentation assay
This assay was performed according to methodology developed in this laboratory (Han and Wyche, 1994) .
